In the head-to-head SURMOUNT-5 trial, tirzepatide produced larger average weight loss than semaglutide at 72 weeks, −20.2% versus −13.7%. Both drugs lower blood glucose and are used in diabetes care, but they act through different mechanisms and carry different prescribing considerations. A clinician can match the choice to your goals and safety profile.
TL;DR:
- SURMOUNT-5 enrolled adults with obesity but no diabetes who reached maximum tolerated doses, so results may not predict outcomes for people with diabetes or those using lower doses.
- Gastrointestinal symptoms clustered around dose increases, and about 3% of tirzepatide participants versus 6% of semaglutide participants stopped treatment because of them.
- Both drugs carry a thyroid tumor warning and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
- People taking insulin or sulfonylureas need a plan to adjust those doses, since combining them with tirzepatide raises the risk of low blood sugar.
Table of Contents
- What are the key differences at a glance?
- What do the trials say about weight loss and A1C?
- How do they work, and how is dosing handled?
- What are the side effects and safety concerns?
- Which one fits your goals?
- What should you expect in practice?
- What does a supervised start look like?
- How do semaglutide and tirzepatide compare on cost and coverage?
- What happens to HbA1c, lipids, and blood pressure?
- What about off-label use and ongoing trials?
- What do we know about long-term safety and results?
- Why tirzepatide's lead is not the whole story
- How can our clinic support you during treatment?
- FAQ
- Sources
What are the key differences at a glance?
Here are the decision facts most readers want first.
- Route and schedule: Both were given as weekly subcutaneous injections in SURMOUNT-5. Labels differ by brand and indication, so diabetes and obesity uses are covered by different products.
- Weight loss in SURMOUNT-5: The trial abstract reports mean percent weight change at week 72 of −20.2% with tirzepatide and −13.7% with semaglutide.
- Common side effects: Gastrointestinal events were the most common adverse events in both groups.
- Boxed warnings: Both labels carry a rodent thyroid C-cell tumor warning and contraindicate use with a personal or family history of medullary thyroid carcinoma or MEN 2, as shown in the semaglutide label.
- Hypoglycemia: Risk rises when tirzepatide is combined with insulin or insulin secretagogues such as sulfonylureas.
- Never combine them: Using tirzepatide together with another tirzepatide product or any GLP-1 receptor agonist is not recommended.
What do the trials say about weight loss and A1C?
SURMOUNT-5 enrolled adults with obesity but without diabetes and compared maximum tolerated doses of each drug. Tirzepatide's advantage was statistically clear, and the abstract also reports greater waist-circumference reductions and a higher share of participants reaching 10% to 25% weight loss.
Mean weight change at 72 weeks: −20.2% with tirzepatide versus −13.7% with semaglutide (P<0.001), per the NEJM report. Roughly six and a half percentage points separated the two drugs.
For glycemic control, the picture is different. Tirzepatide's approval label describes statistically significant HbA1c reductions across multiple SURPASS trials, as monotherapy and as add-on therapy. Semaglutide's diabetes labeling supports its use as well. Both lower A1C, so the diabetes question is less about whether they work and more about which fits the rest of your health picture.
Keep the limits in mind when predicting your own result:
- SURMOUNT-5 studied people without diabetes, and weight loss in people with type 2 diabetes is typically smaller on either drug.
- Participants were on maximum tolerated doses, so results at lower doses may differ.
- The trial was an industry-sponsored study of a defined population, so individual results will vary.
- Clinical commentary notes that percent weight loss differed by sex in trials, and clinicians increasingly look at metabolic markers beyond the scale.
How do they work, and how is dosing handled?
Semaglutide activates the GLP-1 receptor. Tirzepatide activates both the GIP and GLP-1 receptors. Metabolic specialists at Weill Cornell attribute tirzepatide's edge to this dual agonism, which reduces hunger, improves glucose control, and may affect fat-cell metabolism differently than GLP-1 alone. That is a plausible explanation, not a proven single cause.
Dosing basics worth knowing:
- Both drugs are injected once a week and started at a low dose.
- Doses are raised in steps over weeks to months until a maintenance dose is reached.
- Slow escalation is the main tool for limiting nausea and other GI effects.
- Switching between the two is a recognized strategy for plateaus, but it needs careful re-titration because potency and schedules differ, as noted in the NEJM trial report.
- The ADA/EASD 2026 consensus frames these drugs as part of long-term management, not a standalone fix.
Pro Tip: At your first visit, ask for baseline labs, a full medication review (especially insulin and sulfonylureas), and a written plan for handling nausea and constipation during dose increases.
What are the side effects and safety concerns?
Gastrointestinal symptoms dominate both profiles and cluster around dose increases. In SURMOUNT-5, GI side effects led to discontinuation in about 3% of tirzepatide participants and 6% of semaglutide participants, according to the NEJM report.
GI-related discontinuation: about 3% on tirzepatide versus 6% on semaglutide in SURMOUNT-5. The more effective drug in this trial was also the one fewer people stopped for stomach symptoms.
Other safety points to screen for:
- Thyroid warning: Rodent studies showed thyroid C-cell tumors. Both semaglutide and tirzepatide labels contraindicate use with a history of medullary thyroid carcinoma or MEN 2 and advise counseling about symptoms such as a neck lump or trouble swallowing.
- Hypoglycemia: The tirzepatide prescribing highlights list low blood sugar risk with insulin or insulin secretagogues, so those doses often need adjusting.
- Uncommon serious events: Hypersensitivity reactions and acute kidney injury from volume depletion after vomiting or diarrhea can occur. Persistent vomiting, severe abdominal pain, signs of dehydration, or facial swelling should prompt urgent medical care.
- Semaglutide labeling: The Ozempic label carries the same class of thyroid warnings and monitoring guidance.
Which one fits your goals?
Tirzepatide is often favored when maximum average weight loss is the priority, given the SURMOUNT-5 result and the SURPASS glycemic data. Semaglutide remains a solid, well-established option, and the better choice for some people based on tolerability, availability, or other health needs.
Situations that change the conversation:
- Personal or family history of medullary thyroid carcinoma or MEN 2 rules out both drugs.
- Planning a pregnancy needs a discussion before starting either medication.
- Severe GI disorders may make titration harder.
- Current insulin or sulfonylurea use calls for a plan to prevent low blood sugar.
The ADA/EASD consensus stresses that medication works best alongside lifestyle change, behavioral support, and long-term follow-up. Questions to bring to your clinician: What are my goals? What do my labs show? How will we handle side effects? What is the plan if I stall or stop?
What should you expect in practice?
The head-to-head endpoint was measured at 72 weeks, but changes appear well before that. Expect steady, gradual progress rather than quick drops.
- Plan for several months of dose escalation before reaching a maintenance dose.
- Expect nausea or constipation around each increase, and tell your clinician early rather than quitting.
- Check coverage first: it varies by indication and payer, and prior authorization is common for obesity.
- Keep a medication history and ask for a plan to adjust insulin or sulfonylurea doses.
What does a supervised start look like?
Clinic-based care follows a predictable pattern, and ours is nurse-led.
- A first visit usually covers a medication review, baseline labs, and contraindication screening.
- Follow-up visits track dose escalation, side effects, and progress.
- Medication is paired with lifestyle counseling and labs, in line with the ADA/EASD guidance.
How do semaglutide and tirzepatide compare on cost and coverage?
Cost depends far more on your insurance and indication than on the drug itself. Coverage differs by indication: plans often cover these drugs more readily for type 2 diabetes than for obesity alone, and prior authorization, step therapy, or quantity limits are common. The brand matters too. Semaglutide is marketed as Ozempic for diabetes and Wegovy for weight management, while tirzepatide is marketed as Mounjaro for diabetes and Zepbound for weight management, and a plan may cover one product but not its sibling.
Because list prices, rebates, and manufacturer programs change often, we do not quote a figure here. Call your plan, ask whether your indication is covered, and ask your prescriber's office to handle the prior authorization paperwork. Some patients explore telehealth programs, such as Legacy Meds, which describes its self-pay model, but check the program's details and your clinician's guidance before choosing one.
What happens to HbA1c, lipids, and blood pressure?
HbA1c is where both drugs are best documented. The tirzepatide label describes significant A1C reductions across the SURPASS program, and semaglutide's diabetes trials point the same way. For lipids and blood pressure, weight loss itself often improves these markers, so the larger weight reductions seen with tirzepatide may translate to larger secondary benefits, though head-to-head data on those markers are less complete than the weight data.
Standards-of-care guidance underscores that cardiovascular and kidney comorbidities should shape the choice of glucose-lowering therapy, and that GLP-1 receptor agonists and related agents can have benefits across these outcomes. The 2026 pharmacologic standards describe these therapies as core strategies to reduce cardiovascular risk and slow chronic kidney disease progression in people with diabetes. Ask your clinician to recheck lipids and blood pressure alongside A1C so changes are tracked together.
What about off-label use and ongoing trials?
Off-label use means a clinician prescribes a drug for something its label does not list. Both drugs are being studied for conditions beyond diabetes and obesity, and new indications can appear as trial results come in. Because labels change, check the current prescribing information rather than relying on a headline.
Be cautious with anything marketed around these drugs that is not an approved product. Compounded versions, microdosing schedules, and combinations with other injectables are not what the SURMOUNT-5 and SURPASS data describe, so those results do not automatically apply to them. Labeling also says not to combine tirzepatide with other tirzepatide products or any GLP-1 receptor agonist. If you want a clinician-facing view of how compounded options fit the conversation, this practice discussion covers compounding considerations, though the choice belongs in a prescriber's hands.
What do we know about long-term safety and results?
SURMOUNT-5 followed participants for 72 weeks, which is long enough to compare efficacy and early tolerability but not to answer every question about years of use. Longer-term evidence for both drugs comes from extended programs and diabetes outcome work, summarized in the standards-of-care guidance on cardiovascular and kidney outcomes.
What we can say plainly: these are treatments for chronic conditions, and the ADA/EASD consensus emphasizes long-term weight-management planning and psychological support alongside medication. Plan for ongoing follow-up, and ask your clinician what to expect if you stop a medication. Ask how long your clinician expects you to stay on treatment and how maintenance will be handled. A practice-level review of recent science offers additional context on outcomes.
Why tirzepatide's lead is not the whole story
The trial advantage for tirzepatide is real, and we say so without hedging. But a drug that works better on average is not automatically the right drug for you. Tolerability, coverage, other conditions, and what you can sustain for years all matter as much as a percentage point.
What worries us is the idea that an injection can replace the slower work of nutrition, movement, sleep, and follow-up. Strong outcomes can come from pairing medication with behavior and metabolic care, and that takes a clinician who knows your history. Bring this article to your next appointment and use it to ask better questions. The decision should be shared, and it should be safe first.
— Debbie
How can our clinic support you during treatment?
Our services are not substitutes for GLP-1 or dual-agonist medications. What we offer is nurse-led, clinic-based wellness support that some clients use alongside medical treatment: IV vitamin therapy for hydration and energy, peptide services, and recovery support. Browse everything on our services page, or look at our membership plans if you want ongoing supervised care. When you are ready, book a consultation with our nurse team and we will talk through what fits.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
FAQ
How long does it take to lose 20 lbs on tirzepatide?
There is no fixed timeline, because it depends on your starting weight, dose, and how quickly you tolerate escalation. SURMOUNT-5 measured results at 72 weeks, with weight coming off gradually over that period. Your clinician can set a realistic expectation for your case.
Do you lose more muscle on semaglutide or tirzepatide?
We do not have a source comparing muscle loss between the two drugs, so we cannot say one causes more. Changes in body composition can accompany weight loss. Protein intake and resistance exercise are common ways clinicians help protect muscle.
What not to mix with semaglutide?
Do not combine it with any other GLP-1 receptor agonist or a tirzepatide product, since coadministration is not recommended on the labeling. Insulin and sulfonylureas can raise hypoglycemia risk and may need dose changes. Review all your medications with your prescriber.
Why does semaglutide work for me but not tirzepatide?
Individual response varies, and trial averages do not predict every person. Differences in dose reached, tolerability, adherence, and underlying biology can all play a part. Switching is a recognized strategy, but it needs careful re-titration under clinician guidance.
Sources
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity - PubMed
- Reference ID: 5736871
- Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. (1)